ASD Phenotype 3 Treatment Using Membrane Repolarization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for autism spectrum disorder (ASD) are ineffective due to the heterogeneity of the condition, leading to a need for identifying specific subgroups of patients that respond to targeted treatments, as existing approaches fail to account for genetic and molecular variations.
Innovation Solution
A pharmaceutical composition and method for identifying and treating ASD phenotype 3 patients by using a substance that induces repolarization of excitable cell membranes after depolarization, characterized by specific clinical signs and symptoms, and administering bumetanide as a therapeutic agent to stabilize the resting membrane potential.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If a single diagnostic entity approach is used for ASD, then diagnosis remains simple, but treatment effectiveness deteriorates due to heterogeneity
Solution Approach 1:
The patent segments ASD into distinct phenotypic subtypes (ASD phenotype 1, 2, and 3) based on specific clinical signs and symptoms. Each subtype is characterized by a specific combination of symptoms (e.g., ASD phenotype 3 includes gastric ulcer, hyperkinesia, hyperventilation, tachycardia, short neck, hypophosphatemia, McCune-Albright syndrome, seizures, family history of hypertension, hyperkalemia, gastroesophageal reflux, precocious puberty, hyperinsulinemia, increased inflammatory response, family history of cholangiocarcinoma, hearing impairment, hyperchloraemia, family history of diabetes, jointhypermobility, constipation, family history of breast cancer, worsening of ASD core symptoms under benzodiazepines, family history of colorectal cancer, family history of prostatic cancer andhyperalgesia). This segmentation enables tailored treatments for each subtype, resolving the contradiction between diagnostic simplicity and treatment effectiveness.
2Adaptability or versatility
If heterogeneous treatment approaches are tried for all ASD patients, then treatment coverage is broad, but response consistency deteriorates
Solution Approach 1:
The patent applies local quality by prescribing specific treatments targeted at specific phenotypic subtypes. For example, sulforaphane is recommended for ASD phenotype 3 patients with specific symptoms including gastric ulcer,hyperkinesia, hyperventilation, tachycardia, short neck, hypophosphatemia, McCune-Albright syndrome, seizures, family history of hypertension,hyperkalemia, gastroesophageal reflux, precocious puberty,hyperinsulinemia, increased inflammatory response, family history of cholangiocarcinoma, hearing impairment,hyperchloraemia, family history of diabetes, joint hypermobility, constipation, family history of breast cancer, worsening of ASD core symptoms under benzodiazepines, family history of colorectal cancer, family history of prostatic cancer andhyperalgesia. This localized approach ensures treatment consistency and effectiveness for each subtype while maintaining broad coverage across different patient populations.
3Ease of operation
If existing treatments like sulforaphane are used without patient stratification, then treatment application is straightforward, but outcome heterogeneity increases
Solution Approach 1:
The patent implements preliminary action by stratifying patients into distinct phenotypic subtypes before initiating treatment. Clinicians first assess patients for the presence of specific clinical signs and symptoms to identify the appropriate phenotype (ASD phenotype 1, 2, or 3), then select the corresponding treatment protocol. This preliminary classification ensures that treatments like sulforaphane are applied only to appropriate candidates, improving outcome homogeneity while maintaining ease of operation through clear diagnostic criteria and treatment guidelines.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach effectively stratifies ASD patients into responders and non-responders, providing a tailored treatment for ASD phenotype 3 patients, improving core and ancillary symptoms by stabilizing the resting membrane potential of neuronal and pancreatic cells.
Implementation Method 1
a substance capable of inducing repolarization of the membrane of excitable cells after depolarization
Data Source
AI summary
The present invention relates to pharmaceutical compositions for the treatment of a subtype of autism spectrum disorder (ASD) patients. Likewise, the present invention relates to methods of diagnosing a subtype of ASD and methods for identifying patients responding a specific treatment of ASD.